Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder

• Published in: Pharmaceutical research Vol. 19; no. 5; pp. 689 - 695
• Main Authors: DUDDU, Sarma P, SISK, Steven A, NEWMAN, Stephen P, WEERS, Jeffry G, WALTER, Yulia H, TARARA, Thomas E, TRIMBLE, Kevin R, CLARK, Andrew R, ELDON, Michael A, ELTON, Rebecca C, PICKFORD, Matthew, HIRST, Peter H
• Format: Journal Article
• Language: English
• Published: New York, NY Springer 01.05.2002; Springer Nature B.V
• Subjects: Administration, Inhalation; Adult; Biological and medical sciences; Budesonide - administration & dosage; Budesonide - pharmacokinetics; Cross-Over Studies; Female; Gas Chromatography-Mass Spectrometry; General pharmacology; Humans; Isotope Labeling; Lung - metabolism; Male; Medical sciences; Metered Dose Inhalers; Particle Size; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Powders; Radioisotopes; Reproducibility of Results; Respiratory system; Technetium; Tissue Distribution; Human; Delivery system; Budesonide; Corticosteroid; Pharmaceutical technology; Healthy subject; Toxicity; Lung; Antiinflammatory agent; Intrapulmonary administration; Respiratory system; Powder; Blood; Blood plasma; Registered trade mark; Inhaler; Commercial form; Pharmacokinetics; Deposition

To assess the pulmonary deposition and pharmacokinetics of an engineered PulmoSphere powder relative to standard micronized drug when delivered from passive dry powder inhalers (DPIs). Budesonide PulmoSphere (PSbud) powder was manufactured using an emulsion-based spray-drying process. Eight healthy...